1032 OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ESOPHAGECTOMY FOR T1 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A REAL WORLD STUDY
Xiaocen Zhang
DOI: https://doi.org/10.1016/j.gie.2018.04.1365
IF: 10.396
2018-01-01
Gastrointestinal Endoscopy
Abstract:To evaluate benefits and limitations of Endoscopic Submucosal Dissection (ESD) compared to esophagectomy in treating early esophageal squamous cell carcinoma (EESCC). Esophagectomy has been the gold standard for treating EESCC but is related to high perioperative morbidity/mortality and impaired short and long-term quality of life.ESD is a far less invasive method to manage the disease and has been reported to have good results for over 10 years.However, the high risk of nodal metastasis in EESCC patients brings concerns regarding adequacy of ESD and there has been no study directly comparing outcomes of ESD to esophagectomy. This is a single center case-control study.T1a-m2/m3 and T1b EESCC patients receiving ESD between 10/1/2011 and 9/30/2016 at our institution were analyzed as the study group and those receiving esophagectomy during the same period as the control group.Patient and cancer characteristics,procedure parameters,pathology,adverse events and survival data were compared between the two groups. The ESD group contained 322 patients and the esophagectomy group 274 patients.The ESD group had older age (mean 63.5 vs. 62.3 years,p<0.01)),more males (80.1% vs. 70.4%,p<0.01),more T1a (74.5% vs. 27%,p<0.01) and less T1b patients (25.5% vs.73.0%,p<0.01) and larger lesions (median diameter 2.6 vs. 2.0cm,p<0.01).The ESD group had lower perioperative mortality (0.3% vs.1.5%,p=0.19) and fewer non-fatal severe adverse events (15.5% vs. 30.7%,p<0.01), specifically less esophageal fistula (0.3% vs. 16.4%,p<0.01) and less pulmonary complications (0.3% vs. 3.6%,p<0.01).After a median follow up of 21 months (range 6-73 months),the ESD group had a similar rate of all-cause mortality (7.4% vs. 10.9%,p=0.21),lower disease-specific mortality (3.4% vs. 7.4%,p=0.05),and a similar rate of cancer recurrence/metastasis (9.1% vs. 7.4%,p=0.95).Cox regression showed depth of cancer invasion to be the only risk factor for all-cause mortality (T1-m3 or deeper vs. T1-m2, HR=3.54, p=0.04).Subgroup analysis showed no difference in all-cause mortality, disease-specific mortality or recurrence/metastasis rate between the ESD and esophagectomy group in T1a-m2,T1a-m3 or T1b patients.After the two groups were matched for age,gender,presence of a second malignancy,depth of cancer invasion and adjuvant radiotherapy using the propensity score (PSM study),127 pairs were found and the ESD group had a lower rate of severe perioperative adverse events (15.7% vs. 29.9%,p=0.01) but no difference in survival or recurrence/metastasis compared to the esophagectomy group. ESD was found to have much lower perioperative adverse events and no difference in survival or recurrence/metastasis compared to esophagectomy in both T1a and T1b EESCC patients.Prospective studies with longer follow up are needed to find the best treatment for these patients.Tabled 1Table 1. Patient demographics, cancer characteristics, pathology and outcomesESDn=322Esophagectomyn=274p-valueAge (years), mean ±SD63.5±8.362.3±7.40.006Male258 (80.1%)193 (70.4%)0.006Depth of invasion<0.001Lamina propria (T1a-m2)107 (33.2%)24 (8.8%)Mucosa muscularis (T1a-m3)133 (41.3%)50 (18.2%)Submucosa (T1b)82 (25.5%)200 (73.0%)Lymphovascular invasion/nodal metastasis211 (3.4%)36 (13.1%)NALesion diameter3 (cm), median (IQR)2.6 (2.0-3.6)2.0 (1.5-3.0)<0.001En bloc resection317 (98.4%)NANAR0 resection4296 (91.9%)269 (98.2%)<0.001Procedure duration (min), median (IQR)49.0 (36.0-74.0)240.0 (200.0-275.0)<0.001Hospital stay (day), median (IQR)3 (2-4)11 (9-23)<0.001Hospital cost (USD), median (IQR)2812.5 (2218.7-3641.7)10,000.8 (8271.1-12056.5)<0.001Severe perioperative adverse EventsMortality1 (0.3%)4 (1.5%)0.186Non-fatal adverse events49 (15.2%)76 (27.7%)<0.001Esophageal fistula1 (0.3%)45(16.4%)<0.001Delayed bleeding1 (0.3%)2(0.7%)0.597Esophageal perforation4 (1.2%)00.129Pulmonary complications1 (0.3%)10 (3.6%)0.004Esophageal stricture43 (13.4%)27 (9.9%)0.203Adjuvant therapyRepeat Endoscopy/ Surgery11 (3.4%)0 (0%)<0.001Radiotherapy18 (5.6%)1 (0.4%)<0.001Chemotherapy11 (3.4%)11 (4.0%)0.828Oncologic outcomes, follow-up: median 21 (range 6-73) monthsn=297n=258p-valueAll -cause mortality22(7.4%)28 (10.9%)0.209Disease-specific mortality10 (3.4%)19 (7.4%)0.049Recurrence/ metastasis27 (9.1%)23 (8.9%)0.948 Open table in a new tab